• Cardiol Therapeutics announced Phase II MAvERIC results for CardiolRx in recurrent pericarditis were accepted for publication in a forthcoming issue of Journal of the American Heart Association.
• Findings showed treatment was linked to rapid, sustained easing of pain and inflammation, fewer disease flare-ups, and a safety profile viewed as favorable.
• Data were described as supporting ongoing pivotal Phase III MAVERIC trial, which has surpassed 75% enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiol Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605070727PR_NEWS_USPR_____TO53710) on May 07, 2026, and is solely responsible for the information contained therein.